3 results
Primary Objective:To compare the efficacy of BMS-986142 versus placebo on a background of MTX as assessed by ACR20 and ACR70 response rates at week 12.Secondary Objectives:1) Assess additional efficacy outcomes of BMS-986142 at week 12 and over 12…
Primary objectives: -To evaluate the PK profile of OBE001 when administered orally to pregnant women.Secondary objectives: -To evaluate the maternal safety and tolerability of OBE001 when administered orally to pregnant women.-To evaluate the acute…
Primary: To assess the proportion of patients with intervention failure at 12 months after dose reduction, defined as patients who have restarted their initial dose due to (expected) loss of major molecular response.